logo
What Role Does Diet Play in Managing Atopic Dermatitis?

What Role Does Diet Play in Managing Atopic Dermatitis?

Medscape13-06-2025
Eliminating 'problematic' foods or ingredients from the diet is not a sensible measure to apply across all patients with atopic dermatitis (AD), although it may be beneficial for a subset of patients with moderate-to-severe disease who also have documented food allergies. This point was emphasized in several presentations at The World Congress of Pediatric Dermatology (WCPD) 2025 Annual Meeting, held recently in Buenos Aires, Argentina.
'There is currently no role for routine elimination diets in all patients with AD,' said Sandipan Dhar, MD, professor and head of the Department of Pediatric Dermatology at the Institute of Child Health in Kolkata, India, and current vice president of the International Society of Pediatric Dermatology.
Dhar noted that when you google the words 'diet' and 'eczema,' about half of the results come from self-proclaimed 'experts,' 30% from educational websites, and 20% from promotional sites. Among the top 10 results, 80% recommend avoiding milk or dairy, and 50% suggest avoiding soy, wheat, and gluten.
However, only 3%-10% of patients with AD also have food allergies, though that proportion can rise to one third among individuals with moderate-to-severe disease, Dhar explained. 'Remember: Dietary restriction makes no sense in pediatric or adult patients with mild AD.'
Although there are no clear diagnostic criteria, young children with severe AD are more likely to have food allergies, said Dhar. A 2015 population-based cohort study of more than 4000 infants found that those with AD had a sixfold increased risk for food allergy to cow's milk, egg, or peanuts.
Effectiveness of Elimination Diets
Dhar stated that a review of the literature shows 'mixed results' regarding the usefulness of elimination diets in AD, with few randomized, double-blind studies published in the past 20 years supporting a role for food allergy in clinical manifestations of the disease. A 2008 Cochrane review concluded that there is 'little evidence' supporting the use of exclusion diets in unselected individuals with AD.
In 2009, Dhar led an open-label, uncontrolled pilot study in a selected group of 100 infants and children with severe AD. Participants were asked to strictly avoid milk and dairy products, all types of nuts, egg, marine fish, shrimp, eggplant, and soy for 3 weeks. The study found a statistically significant reduction in disease severity scores.
However, Dhar clarified that he now critiques his own study ('this is how science progresses') and that the concept of strict food avoidance has evolved. In the past decade, numerous studies have shown that delaying the introduction of foods such as milk, egg, wheat, and peanuts during infancy actually increases the risk of developing allergies to those foods. In the landmark 2015 LEAP trial from the UK, early introduction of peanuts starting at 4 months of age in infants aged 4-11 months with severe AD and egg allergy significantly reduced the risk for peanut allergy compared to those who avoided peanuts until age 5.
María Fernanda Greco, MD, a panelist at the congress and head of Pediatric and Adolescent Dermatology at the British Hospital in Buenos Aires, Argentina, agreed that there is no single dietary approach suitable for all patients with AD.
However, she emphasized that 'there is growing interest in the role of the gut microbiome in skin health' and suggested that enhancing the gut barrier through diets that promote intestinal health, as well as probiotic supplementation (eg, Lactobacillus and Bifidobacterium found in yogurt and fermented foods) or prebiotics (found in garlic, onions, and bananas), may help improve the skin barrier and reduce disease severity in the short term. For example, a 2021 randomized Polish study found that a probiotic preparation containing three strains ( Lactobacillus rhamnosus ŁOCK 0900, L rhamnosus ŁOCK 0908, and L casei ŁOCK 0918) increased the likelihood of improvement by sixfold over 3 months in children younger than 2 years with AD and cow's milk protein allergy. However, the benefits did not persist after 9 months.
Supplementing with omega-3 polyunsaturated fatty acids may also help modulate inflammatory responses and improve symptoms, she added.
'It's difficult to take a definitive stance [on the role of diet in AD], but I believe that with each patient, we need to assess whether they might benefit from supplementation, food avoidance, or allergy testing,' Greco concluded.
Dhar closed the session by emphasizing that until future studies clarify the relationship between food allergies, AD, and the immune pathways that regulate tolerance and immediate hypersensitivity, clinical decisions about elimination diets should be based on reflective, cautious interpretation of the available evidence.
And if an elimination diet is pursued, it should be personalized 'based on the patient's needs, the severity of eczema, and documented correlations between dietary intake and skin flares or food allergies — without neglecting nutritional balance,' he concluded.
Dhar disclosed advisory or thought-leader roles with some pharmaceutical companies, though his presentation did not reference any commercial products. Greco declared having no relevant financial conflicts of interest.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Enable Injections Announces enFuse® System Regulatory Approval in Brazil and MRHA Medical Device Registration in the UK
Enable Injections Announces enFuse® System Regulatory Approval in Brazil and MRHA Medical Device Registration in the UK

Yahoo

time3 hours ago

  • Yahoo

Enable Injections Announces enFuse® System Regulatory Approval in Brazil and MRHA Medical Device Registration in the UK

CINCINNATI, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. ('Enable'), a healthcare innovation company developing and manufacturing the enFuse® on-body drug delivery system, announced today that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or ANVISA) approved the enFuse system for administration of medication subcutaneously. Approval of enFuse technology by ANVISA demonstrates that the enFuse on-body injector and enFuse syringe and vial transfer systems adhere to applicable Brazilian safety and quality standards and requirements, allowing distribution throughout the country. The approval in Brazil marks a milestone in Enable's partnership with Sobi, announced in September 2024, with plans to develop and distribute the enFuse system for the administration of Empaveli®/Aspaveli® in Sobi territories. 'Obtaining approval for the enFuse system in Brazil is an important regulatory milestone that underscores our commitment to bring our innovative technology to as many patients as possible, globally, who could benefit from a more comfortable administration experience,' said Michael D. Hooven, Chairman and CEO of Enable Injections. 'By continuing to collaborate closely with our pharmaceutical partners, we remain steadfast in our mission to improve the lives of patients and caregivers through our wearable enFuse technology, minimizing disruption to their daily lives.' In addition, the enFuse technology is registered in the UK with the United Kingdom's Medicines and Healthcare products Regulatory Agency (UK MHRA) as of June 6, 2025 and received European Union Medical Device Regulation (EU MDR) CE Mark in March 2025. The enFuse on-body injector features hands-free, hidden needle drug delivery through a simple injection under the skin instead of intravenously, which is time-consuming and resource intensive. The enFuse system is designed to enhance the patient treatment experience by streamlining and improving at-home self-administration or in-clinic subcutaneous delivery of large volumes of pharmaceutical and biologic therapeutics. About Enable InjectionsCincinnati-based Enable Injections is a global healthcare innovation company committed to improving the patient treatment experience through the development and manufacturing of the enFuse on-body drug delivery system. An innovative wearable technology, the enFuse system is designed to deliver large volumes of pharmaceutical and biologic therapeutics via subcutaneous administration, with the aim of improving convenience, supporting superior outcomes, and advancing healthcare system economics. Enable is currently working with a number of pharmaceutical partners to conduct clinical trials and plan for joint commercial launch of their therapies in combination with the enFuse technology. Enable's enFuse technology received its first combination product U.S. FDA approval in 2023. For more information, visit Media Contact:Molly DevlinReal Chemistrymdevlin@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Ultrasound-Based Diagnosis of Early PsA Remains Elusive
Ultrasound-Based Diagnosis of Early PsA Remains Elusive

Medscape

time6 hours ago

  • Medscape

Ultrasound-Based Diagnosis of Early PsA Remains Elusive

BOGOTÁ, Colombia — Early detection and treatment of psoriatic arthritis (PsA) can prevent joint damage and improve long-term disease outcomes. But, to date, no biomarker has emerged that can reliably diagnose early PsA. At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2025 Annual Meeting and Trainee Symposium, researchers presented the latest results from a multiyear international effort to create an ultrasound-based scoring system for enthesitis that can be used to help diagnose early disease. Enthesitis, or inflammation, in the areas where tendons and ligaments attach to bones is a common feature in PsA and often among the first manifestations of the disease. The Diagnostic Ultrasound Enthesitis Tool (DUET) study, led by Lihi Eder, MD, of the University of Toronto, Toronto, Ontario, Canada, Sibel Aydin, MD, of the University of Ottawa, Ottawa, Ontario, and Gurjit Kaeley, MD, of the University of Florida College of Medicine in Jacksonville, Florida, sought to develop a new sonographic enthesitis scoring system to assist with the diagnosis of PsA. Eder, who presented the most recent findings from DUET at the conference, described the goal of the study as an ultrasound-based scoring system that can reliably distinguish PsA, scans as few sites as possible, and is reproducible, consistent, and simple to calculate. Patella, Triceps, and Achilles Tendon Sites Best in Discriminating Conditions Eder and her colleagues recruited 213 patients with rheumatologist-confirmed PsA (mean, 1.6 years since diagnosis), 100 patients with dermatologist-confirmed psoriasis and no history of PsA, and 106 control patients who had been seen by rheumatologists for noninflammatory musculoskeletal issues. None of the subjects were taking biologic therapies. The researchers scanned 16 entheseal sites in the upper and lower extremities for each patient. After a preliminary analysis, they chose six sites as the basis for their score and evaluated nearly 50 different combinations of sites. The final DUET score integrated both inflammatory and structural findings from the scanned sites. DUET scores were significantly higher in people with PsA than in control individuals, regardless of age, sex, and BMI, Eder reported. The patella, triceps, and Achilles tendon were the sites that discriminated best between patients with PsA and control individuals. While the DUET score had a specificity of over 70%, sensitivity was only about 50% across age groups, meaning that half the patients with early PsA had a negative score. When people presented with one or more tender entheses among the scanned sites, sensitivity rose to 60%. The sensitivity findings 'may be explained by the fact that enthesitis in joints is not seen in all patients with psoriatic arthritis,' Eder said. 'It is a heterogeneous disease.' 'We should be aware of the limitation that this tool that does not recognize all patients with PsA,' Eder continued. 'But the sensitivity improves when tender entheses are present,' she noted, adding that her group is conducting additional studies to validate DUET in real-world settings. The DUET study, which has funding from industry, is a GRAPPA-led initiative. GRAPPA co-founder and current president Arthur Kavanaugh, MD, of the University of California, San Diego, said in an interview during the conference that the results were clinically meaningful, even if not as discriminatory as hoped. 'In the clinic, you don't necessarily use ultrasound on people if they're not tender,' Kavanaugh said. 'I think everyone had wanted a very simple answer, that this [scoring system] was going to be perfect,' he added. 'And you saw a very thorough attempt to try and make it so. But the data are the data.' Philip Mease, MD, of the Swedish Medical Center in Seattle, a GRAPPA co-founder and past president, concurred. The sensitivity numbers 'were less than I would have hoped for,' he said. 'But that's the nature of the beast. This is a really difficult thing to assess.' Mease added that it was helpful for him to learn which scanning sites are the most informative. 'This will be very useful for people who do ultrasound as part of their practice,' he said.

Scientists find 74-million-year-old mammal fossil in Chile
Scientists find 74-million-year-old mammal fossil in Chile

Yahoo

time7 hours ago

  • Yahoo

Scientists find 74-million-year-old mammal fossil in Chile

Scientists have discovered the fossil of a tiny mouse-sized mammal that lived in the time of the dinosaurs in Chilean Patagonia. "Yeutherium pressor" weighed between 30 and 40 grams (about one ounce) and lived in the Upper Cretaceous period, about 74 million years ago. It is the smallest mammal ever found in this region of South America, dating back to the era when it was part of a continental land mass known as Gondwana. The fossil consists of "a small piece of jaw with a molar and the crown and roots of two other molars," said Hans Puschel, who led the team of scientists from the University of Chile and Chile's Millennium Nucleus research center on early mammals. The discovery was published this month in the British scientific journal Proceedings of the Royal Society B. Researchers found the fossil in the Rio de las Las Chinas Valley in Chile's Magallanes region, about 3,000 kilometers (1,864 miles) south of Santiago. Despites its similarity to a small rodent, "Yeutherium pressor" was a mammal that must have laid eggs, like the platypus, or carried its young in a pouch like kangaroos or opossums. The shape of its teeth suggests that it probably had a diet of relatively hard vegetables. Just like the dinosaurs with whom it co-existed, the tiny mammal abruptly went extinct at the end of the Cretaceous period, about 66 million years ago. ps/axl/ksb/jgc/sla

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store